1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-30.29%
Cash & equivalents declining -30.29% while Drug Manufacturers - Specialty & Generic shows 1.63% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
-9.13%
Short-term investments yoy growth below half the Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos would question if the firm lacks surplus cash or is facing liquidity stress.
-10.50%
Below half the Drug Manufacturers - Specialty & Generic median of 0.00% yoy growth. Jim Chanos might see inadequate liquidity buildup relative to peers. Verify free cash flow trends.
-37.18%
Receivables growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a serious red flag in ballooning receivables.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.91%
Below half the Drug Manufacturers - Specialty & Generic median of 0.29%. Jim Chanos would question if the company faces working capital strain.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.91%
Below half the Drug Manufacturers - Specialty & Generic median of 0.95%. Jim Chanos might see potential stagnation or distress vs. peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-50.64%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
-50.64%
Below half Drug Manufacturers - Specialty & Generic median of 1.52%. Joel Greenblatt sees more conservative short-term leverage than peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-50.64%
Below half Drug Manufacturers - Specialty & Generic median of 0.07%. Joel Greenblatt sees a much lower liability expansion vs. peers.
No Data
No Data available this quarter, please select a different quarter.
-7.97%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects poor profitability or large dividend drains.
No Data
No Data available this quarter, please select a different quarter.
-2.97%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potential red flag for complicated equity transactions.
-7.01%
Below half Drug Manufacturers - Specialty & Generic median of 1.74%. Jim Chanos suspects slower net worth growth or losses vs. peers.
-10.91%
Below half Drug Manufacturers - Specialty & Generic median of 0.75%. Jim Chanos suspects a major slowdown or distress.
-9.13%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees potential underinvestment or forced liquidation vs. peers.
No Data
No Data available this quarter, please select a different quarter.
30.29%
Below half of Drug Manufacturers - Specialty & Generic median -0.28%. Joel Greenblatt sees stronger deleveraging or cash accumulation vs. peers.
